» Articles » PMID: 38659828

Musashi-2 (MSI2) Regulation of DNA Damage Response in Lung Cancer

Overview
Journal Res Sq
Date 2024 Apr 25
PMID 38659828
Authors
Affiliations
Soon will be listed here.
Abstract

Lung cancer is one of the most common types of cancer worldwide. Non-small cell lung cancer (NSCLC), typically caused by and driver mutations, represents the majority of all new lung cancer diagnoses. Overexpression of the RNA-binding protein (RBP) Musashi-2 (MSI2) has been associated with NSCLC progression. To investigate the role of MSI2 in NSCLC development, we compared the tumorigenesis in mice with lung-specific -activating mutation and deletion, with and without deletion (KPM2 versus KP mice). KPM2 mice showed decreased lung tumorigenesis in comparison with KP mice. In addition, KPM2 lung tumors showed evidence of decreased proliferation, but increased DNA damage, marked by increased levels of phH2AX (S139) and phCHK1 (S345), but decreased total and activated ATM. Using cell lines from KP and KPM2 tumors, and human NSCLC cell lines, we found that MSI2 directly binds mRNA and regulates its translation. MSI2 depletion impaired DNA damage response (DDR) signaling and sensitized human and murine NSCLC cells to treatment with PARP inhibitors and . Taken together, we conclude that MSI2 supports NSCLC tumorigenesis, in part, by supporting repair of DNA damage by controlling expression of DDR proteins. These results suggest that targeting MSI2 may be a promising strategy for lung cancers treated with DNA-damaging agents.

References
1.
Gridelli C, Rossi A, Carbone D, Guarize J, Karachaliou N, Mok T . Non-small-cell lung cancer. Nat Rev Dis Primers. 2016; 1:15009. DOI: 10.1038/nrdp.2015.9. View

2.
Ding L, Getz G, Wheeler D, Mardis E, McLellan M, Cibulskis K . Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 2008; 455(7216):1069-75. PMC: 2694412. DOI: 10.1038/nature07423. View

3.
Fennell D, Porter C, Lester J, Danson S, Blackhall F, Nicolson M . Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial. EClinicalMedicine. 2022; 52:101595. PMC: 9386392. DOI: 10.1016/j.eclinm.2022.101595. View

4.
Chakravarthy R, Mnich K, Gorman A . Nerve growth factor (NGF)-mediated regulation of p75(NTR) expression contributes to chemotherapeutic resistance in triple negative breast cancer cells. Biochem Biophys Res Commun. 2016; 478(4):1541-7. DOI: 10.1016/j.bbrc.2016.08.149. View

5.
Villaruz L, Jones H, Dacic S, Abberbock S, Kurland B, Stabile L . ATM protein is deficient in over 40% of lung adenocarcinomas. Oncotarget. 2016; 7(36):57714-57725. PMC: 5295384. DOI: 10.18632/oncotarget.9757. View